<乌鸦传媒>FDA OKs New Topical for Inflammatory Rosacea Almost half of patients clear of lesions or nearly so with benzoyl peroxide 5% cream (Epsolay) Apr 25, 2022
<乌鸦传媒>Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
<乌鸦传媒>Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
<乌鸦传媒>Response in Kids With Psoriasis Maintained Long Term With IL-17A Inhibitor At least 75% improvement at 108 weeks in patients treated with ixekizumab Apr 13, 2022
<乌鸦传媒>Smoker's Painless Skin Nodules Flag a Fatal Diagnosis Skin metastasis was the first sign for the otherwise asymptomatic patient Apr 04, 2022
<乌鸦传媒>First Topical Therapy for Facial Angiofibroma Nabs FDA Approval New alternative to dermabrasion, laser treatment, surgery Apr 04, 2022
<乌鸦传媒>Chronic Spontaneous Urticaria Responds Quickly to BTK Inhibitor AAD data also promising for therapies in psoriasis, pyoderma gangrenosum Mar 31, 2022
<乌鸦传媒>Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factors No reduction in vascular inflammation with apremilast but significant reduction in body fat Mar 30, 2022
<乌鸦传媒>Meta-Analysis of Atopic Dermatitis Drugs Favors Two JAK Inhibitors Small advantages for abrocitinib, upadacitinib, but data still accumulating for all the players Mar 30, 2022
<乌鸦传媒>Toward More Uniform Methotrexate Dosing in Psoriasis International expert group urges common standards Mar 30, 2022
<乌鸦传媒>Jada Pinkett Smith's Alopecia The condition at the center of this year's Academy Awards drama Mar 29, 2022
<乌鸦传媒>Significant Improvement in Vitiligo With JAK Inhibitor Therapy Durable improvement in pigmentation with topical ruxolitinib, oral ritlecitinib Mar 29, 2022
<乌鸦传媒>Atopic Dermatitis: Promising Data for New Mechanistic Approach Rapid responses in a majority of patients in small trial of eblasakimab Mar 28, 2022
<乌鸦传媒>Targeted Antibody Provides Significant Relief From Itchy Nodular Condition Dupilumab reduces itch, lesion count in first phase III trial for prurigo nodularis Mar 28, 2022
<乌鸦传媒>Dramatic, Durable Hair Growth With Oral JAK Inhibitor Oral baricitinib superior to placebo at 36 weeks in BRAVE-AA1 and BRAVE-AA2 trials Mar 27, 2022
<乌鸦传媒>Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
<乌鸦传媒>Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
<乌鸦传媒>Clinic-Based Hidradenitis Suppurativa Surgery Gets High Marks From Patients High satisfaction after three-fourths of procedures, despite frequent recurrences Mar 17, 2022
<乌鸦传媒>Extension Study Confirms JAK Inhibitor's Activity in Atopic Dermatitis EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment Mar 16, 2022
<乌鸦传媒>FDA Warns on Using Surgical Device for Aesthetic Skin Procedures Agency details potentially life-threatening adverse events with plasma-generating device Mar 14, 2022
<乌鸦传媒>Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
<乌鸦传媒>Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
<乌鸦传媒>Predicting Treatment Response in Inflammatory Muscle Disorders Swedish registry study elicits factors associated with improvement Feb 16, 2022
<乌鸦传媒>Acute Muscle Weakness and Skin Rash Following a Lupus Diagnosis Clinicians consider many differentials Feb 14, 2022
<乌鸦传媒>Two Years On, Tremfya Still Shines in Psoriatic Arthritis Efficacy increases in long-term extension data Feb 10, 2022
<乌鸦传媒>Hair Loss Drugs Ranked in Order of Efficacy Meta-analysis attempts a head-to-head comparison Feb 07, 2022
<乌鸦传媒>Evidence Begins to Gel for Atopic Dermatitis, Multiple Comorbid Conditions Atopic, metabolic, cardiovascular, and mental health conditions cited in guideline update Feb 02, 2022
<乌鸦传媒>Six Medical 乌鸦传媒 With the Highest Hourly Wages Plastic and orthopedic surgery top the list Jan 27, 2022
<乌鸦传媒>Psoriasis Patients, Docs Want to Do More to Prevent Heart Problems Despite well-known cardiovascular risks, most patients currently undertreated Jan 19, 2022
<乌鸦传媒>FDA OKs Two Oral JAK Inhibitors for Refractory Atopic Dermatitis Once-daily abrocitinib and upadacitinib join topical ruxolitinib in expanding AD market Jan 18, 2022
<乌鸦传媒>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<乌鸦传媒>Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<乌鸦传媒>IL-13 Inhibitor Approved for Adults With Atopic Dermatitis Significantly greater lesion clearance with tralokinumab in placebo-controlled studies Dec 28, 2021
<乌鸦传媒>Doc Fired After Standing Up to Private Equity; RFK Jr.'s Anti-Vax Machine This past week in healthcare investigations Dec 22, 2021
<乌鸦传媒>Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
<乌鸦传媒>Think TikTok Is Smarter Than Me? Then I'm Not the Right Doctor for You Modern times have fundamentally altered the landscape of healthcare Nov 30, 2021
<乌鸦传媒>Signs of Relief From 'Therapeutic Drought' in Atopic Dermatitis Encouraging results from pipeline agents targeting T乌鸦传媒-specific inflammation Nov 09, 2021
<乌鸦传媒>Could This Biologic Drug Work in Patients Lacking Its Target? Bizarre finding with omalizumab Nov 07, 2021
<乌鸦传媒>Dramatic Responses in Cutaneous Sarcoidosis With JAK Inhibitor More than 80% reduction in disease activity in case series of tofacitinib treatment Nov 07, 2021
